- Home
- MBRX vs HIND Comparison
MBRX vs HIND Comparison
Compare MBRX & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBRX | HIND |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 28.0M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MBRX | HIND |
|---|---|---|
| Price | $7.24 | $5.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $125.00 | N/A |
| AVG Volume (30 Days) | ★ 105.9K | N/A |
| Earning Date | 11-13-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.01 | N/A |
| 52 Week High | $91.25 | N/A |
Technical Indicators
Market Signals| Indicator | MBRX | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 89.96 | 44.10 |
| Support Level | $0.26 | $4.81 |
| Resistance Level | $7.75 | $5.37 |
| Average True Range (ATR) | 0.29 | 0.37 |
| MACD | 0.83 | 0.03 |
| Stochastic Oscillator | 93.19 | 54.02 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.